Chronic high-fat diets blunt the brain’s pleasure response to rich foods by impairing NAcLat→VTA signaling in mice.
Eli Lilly (LLY) and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy ...
BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by ...